Upregulation of PTTG1 is associated with poor prognosis in prostate cancer
Standard
Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. / Fraune, Christoph; Yehorov, Serhiy; Luebke, Andreas M; Steurer, Stefan; Hube-Magg, Claudia; Büscheck, Franziska; Höflmayer, Doris; Tsourlakis, Maria Christina; Clauditz, Till S; Simon, Ronald; Sauter, Guido; Weidemann, Sören; Dum, David; Kind, Simon; Minner, Sarah; Schlomm, Thorsten; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Burandt, Eike.
In: PATHOL INT, Vol. 70, No. 7, 07.2020, p. 441-451.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Upregulation of PTTG1 is associated with poor prognosis in prostate cancer
AU - Fraune, Christoph
AU - Yehorov, Serhiy
AU - Luebke, Andreas M
AU - Steurer, Stefan
AU - Hube-Magg, Claudia
AU - Büscheck, Franziska
AU - Höflmayer, Doris
AU - Tsourlakis, Maria Christina
AU - Clauditz, Till S
AU - Simon, Ronald
AU - Sauter, Guido
AU - Weidemann, Sören
AU - Dum, David
AU - Kind, Simon
AU - Minner, Sarah
AU - Schlomm, Thorsten
AU - Huland, Hartwig
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Burandt, Eike
N1 - © 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
PY - 2020/7
Y1 - 2020/7
N2 - Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness.
AB - Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness.
U2 - 10.1111/pin.12938
DO - 10.1111/pin.12938
M3 - SCORING: Journal article
C2 - 32314536
VL - 70
SP - 441
EP - 451
JO - PATHOL INT
JF - PATHOL INT
SN - 1320-5463
IS - 7
ER -